GlassScriptPhysician profile
Rene Peleman
NPI 1225046170
$37,769.47
in general payments reported to CMS, 2019-2025
41 companies · $3,809 in 2025
The $3,809 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,057 · 2020: $4,628 · 2021: $4,050 · 2022: $7,131 · 2023: $6,883 · 2024: $3,212 · 2025: $3,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,584 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,250 · Education: $69.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,584.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,250.00 |
| Education | $69.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,000.60 | 2019-2025 | |
| Janssen Biotech, INC. | $1,947.69 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,686.34 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,300.31 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,121.79 | 2019-2025 | Epclusa, Livdelzi |
| Regeneron Healthcare Solutions, INC. | $804.52 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $516.47 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $489.60 | 2021-2024 | Zeposia |
| Genzyme Corporation | $368.65 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $274.92 | 2019-2024 | |
| Madrigal Pharmaceuticals | $254.45 | 2025 | Rezdiffra |
| Pfizer INC. | $243.16 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $242.22 | 2024-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $212.56 | 2023-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $204.60 | 2022-2025 | Ibsrela |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $186.92 | 2024-2025 | Voquezna |
| Amgen INC. | $172.20 | 2022-2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $159.68 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $146.69 | 2022-2025 | |
| Daiichi Sankyo INC. | $125.71 | 2022-2025 | Injectafer |
| Lilly USA, LLC | $122.88 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $117.78 | 2019-2022 | |
| Vivus LLC | $106.44 | 2021-2024 | Qsymia |
| Capsovision, INC. | $103.38 | 2023-2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $99.91 | 2022-2023 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $96.24 | 2020 | |
| Allergan, INC. | $93.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $82.68 | 2022 | |
| Endo Pharmaceuticals INC. | $75.14 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $60.58 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $60.18 | 2021-2023 | |
| Celltrion USA INC. | $39.32 | 2024-2025 | Vegzelma, Zymfentra |
| Csl Behring | $36.58 | 2019-2020 | |
| Redhill Biopharma INC. | $35.65 | 2021 | |
| Shire North American Group INC | $34.64 | 2019 | |
| Romark Laboratories, Lc | $33.22 | 2020 | |
| W. L. Gore & Associates, INC. | $32.11 | 2022-2023 | Gore Cardioform Septal Occluder |
| Mylan Institutional INC. | $24.05 | 2023 | Hulio |
| Astrazeneca Pharmaceuticals LP | $23.18 | 2022 | |
| Ucb, INC. | $17.53 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Peleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.